PHGE | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

34.66%

1 Month

46.31%

3 Months

76.38%

6 Months

1,051.38%

1 Year

812.26%

2 Year

735.88%

Key data

Stock price

$5.75

P/E Ratio

N/A

DAY RANGE

$5.30 - $6.94

EPS

-$7.37

52 WEEK RANGE

$0.24 - $8.50

52 WEEK CHANGE

$859.93

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-19-2025

BETA

0.88

PUBLIC FLOAT

AVERAGE 10 VOLUME

$54,523

AVERAGE 30 VOLUME

$92,690

Company detail

CEO: Jonathan E. Solomon
Region: US
Website: biomx.com
Employees: 120
IPO year: 2019

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated

PHGE - BiomX Inc